Comprehensive analysis of Edelweiss MSCI I D & W H 45 Index Fund (G) (41710) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Edelweiss Asset Mgt Ltd
The Scheme will invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors. However, there is no assurance that the investment objective of the Scheme will be realized and the Scheme does not assure or guarantee any returns.
A comprehensive at-a-glance view of key mutual fund health indicators
Good Returns
High Risk
Moderate Expenses
Balanced Mix
Established Team
Average Quality
Showing 1Y NAV history
Performance across different time periods
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Outperformance vs benchmark
Recent performance momentum
Historical performance consistency
Market exposure level
Fund management costs
Fund manager experience
Risk-adjusted returns
Assets under management
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 11.47% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 11.45% |
| Max Healthcare Institute Ltd | Healthcare | 7.08% |
| Max Healthcare Institute Ltd | Healthcare | 6.77% |
| Cipla Ltd | Pharmaceuticals | 6.14% |
| Cipla Ltd | Pharmaceuticals | 6.07% |
| Divis Laboratories Ltd | Pharmaceuticals | 5.80% |
| Divis Laboratories Ltd | Pharmaceuticals | 5.51% |
| Dr Reddys Laboratories Ltd | Pharmaceuticals | 5.35% |
| ELI LILLY & CO | Debt Others | 5.33% |
Compare against Index Fund category average
This comparison shows how the fund performs relative to the Index Fund category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Index Fund category
| Fund Name | NAV | 6M | 1Y | 3Y |
|---|---|---|---|---|
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (IDCW) | ₹1233.29 | 6.17% | 11.30% | N/A |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (G) | ₹1233.29 | 6.17% | 11.30% | N/A |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (G) | ₹1229.16 | 6.09% | 11.14% | N/A |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (IDCW) | ₹1229.15 | 6.09% | 11.14% | N/A |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (G) | ₹1199.62 | 4.94% | 9.12% | N/A |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (IDCW | ₹1199.62 | 4.94% | 9.12% | N/A |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (IDCW) | ₹1195.53 | 4.86% | 8.96% | N/A |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (G) | ₹1195.51 | 4.86% | 8.96% | N/A |
| HDFC BSE Sensex Index Fund - Direct | ₹790.24 | 7.25% | 6.29% | 17.66% |
| HDFC BSE Sensex Index Fund - Regular | ₹771.61 | 7.17% | 6.12% | 17.46% |
A seasoned investment professional with over 5 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.